Standout Papers

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia 2011 2026 2016 2021 3.8k
  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (2014)
    Shannon L. Maude, Noelle V. Frey et al. New England Journal of Medicine
  2. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (2013)
    Stephan A. Grupp, Michael Kalos et al. New England Journal of Medicine
  3. Current concepts in the diagnosis and management of cytokine release syndrome (2014)
    Daniel W. Lee, Rebecca Gardner et al. Blood
  4. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (2011)
    Michael Kalos, Bruce L. Levine et al. Science Translational Medicine
  5. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015)
    David Porter, Wei‐Ting Hwang et al. Science Translational Medicine
  6. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma (2010)
    Alice L. Yu, Andrew L. Gilman et al. New England Journal of Medicine
  7. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo (2009)
    Michael C. Milone, Jonathan D. Fish et al. Molecular Therapy
  8. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges (2020)
    Stéphane Depil, Philippe Duchâteau et al. Nature Reviews Drug Discovery
  9. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies (2014)
    Shannon L. Maude, David M. Barrett et al. The Cancer Journal
  10. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia (2015)
    Shannon L. Maude, David T. Teachey et al. Blood
  11. Antibody-modified T cells: CARs take the front seat for hematologic malignancies (2014)
    Marcela V. Maus, Stephan A. Grupp et al. Blood
  12. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy (2013)
    David T. Teachey, Susan R. Rheingold et al. Blood
  13. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia (2016)
    Julie C. Fitzgerald, Scott L. Weiss et al. Critical Care Medicine
  14. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma (2019)
    Julie R. Park, Susan G. Kreissman et al. JAMA
  15. In vivo hematopoietic stem cell modification by mRNA delivery (2023)
    Laura Breda, Tyler E. Papp et al. Science
  16. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy (2024)
    Bruce L. Levine, Marcelo C. Pasquini et al. Nature Medicine

Immediate Impact

7 by Nobel laureates 32 from Science/Nature 210 standout
Sub-graph 1 of 12

Citing Papers

100 years of the Warburg effect: A cancer metabolism endeavor
2024 Standout
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
2024 Standout
3 intermediate papers

Works of Stephan A. Grupp being referenced

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
2024 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Stephan A. Grupp 20863 3732 2688 8804 7996 322 28.5k
David L. Porter 15738 1907 1279 6177 4727 205 18.9k
David G. Maloney 14619 11152 3185 7903 4268 493 29.4k
David T. Teachey 10348 2830 2529 4836 3671 191 15.1k
Maryalice Stetler‐Stevenson 8719 2164 1169 6069 4234 228 15.4k
Renier J. Brentjens 14711 980 646 6602 5037 194 17.7k
David M. Barrett 9747 1243 1276 3892 3010 130 13.7k
Elizabeth J. Shpall 8730 8580 1515 5720 4625 617 20.4k
Michael C. Milone 11138 776 461 5721 4395 134 15.1k
Crystal L. Mackall 6851 2240 505 8317 3141 167 15.7k
Crystal L. Mackall 9385 786 629 4754 3450 146 12.4k

All Works

Loading papers...

Rankless by CCL
2026